Novogene, a leading global provider of genomic services and solutions, has entered into an agreement with Illumina, for the procurement of 10 additional units of Illumina’s state-of-the-art next-generation sequencing platform, the NovaSeq™ X Plus, fortifying its position at the forefront of the genomic revolution.

Novogene has been an early adopter of the NovaSeq™ X Plus. Since the introduction of NovaSeq™ X Plus in April 2023, Novogene has rapidly deployed the platform across its laboratories worldwide, including China, the United States, and the United Kingdom. Leveraging the high throughput and sequencing cost efficiency of this latest sequencer, Novogene has empowered genomic researchers for larger-scale sequencing and scientific exploration.

Novogene remains steadfast on the focus to ensure scientists worldwide with high-quality, and efficient services. In line with this commitment, the strategic acquisition of ten additional units of NovaSeq™ X Plus Platforms aims to enhance Novogene’s global service capacities. These sequencers will be deployed in our regional laboratories, including those in Singapore and Japan, to bolster our service capabilities.

“We take immense pride in our collaboration with Novogene, a global leader in commercial services, as we strive to broaden the scope of genomics through our revolutionary NovaSeq X Plus. Our enduring partnership with Novogene has spanned over a decade, during which both companies have worked relentlessly to democratize access to genomics worldwide. We have utmost confidence in Novogene’s continued commitment to providing genomics researchers globally with reliable, swift, and cost-effective Next-Generation Sequencing (NGS) service.” Susan Tousi, chief commercial officer of Illumina.

The longstanding partnership between Novogene and Illumina dates to 2014 when Novogene became one of the first global users of Illumina’s high-throughput sequencing system, HiSeq X Ten. Over the past decade, Novogene has consistently been among the first adopt the various illumina platforms, from HiSeq 2000/2500/4000, to MiSeq, NextSeq 500, NovaSeq 6000, and now, NovaSeq™ X Plus solidifying its position as one of Illumina’s premier global business partners.

Dr. Ruiqiang Li, CEO of Novogene highlighted:“Throughout our journey, Illumina has remained a pivotal partner for Novogene. Over more than a decade of collaboration, we’ve witnessed remarkable growth together. Illumina’s globally leading equipment provides the foundation for breakthroughs in cutting-edge research. Novogene, drawing upon its extensive project experience, translates and applies these innovations worldwide. Currently operating in over 90 countries across 6 continents, Novogene’s global presence is a testament to the strong alliance between these two companies, driving the industry forward and fostering continuous development”

In recent years, Novogene has consistently embraced the latest technologies and expanded services on these technology platforms, including PacBio’s Revio third-generation sequencer and Thermo Fisher’s Orbitrap Astral high-resolution mass spectrometer. Deployed across multiple laboratories within Novogene’s global service network, these cutting-edge instruments broaden the range of services and solutions available to customers.

Looking ahead, Novogene remains dedicated to its customer-centric approach and its commitment to collaborating with global leaders like Illumina to empower life science research. Novogene will continue to stand as your trusted partner in genomics.